ReShape Lifesciences Share Price OTC Markets
Equities
RSLS
US7611236032
Advanced Medical Equipment & Technology
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
5.09 USD | +23.84% | -.--% | -.--% |
05-15 | ReShape Lifesciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
05-15 | Transcript : ReShape Lifesciences Inc., Q1 2024 Earnings Call, May 15, 2024 |
Sales 2024 * | 9.99M 784M | Sales 2025 * | 11.99M 941M | Capitalization | 5.98M 469M |
---|---|---|---|---|---|
Net income 2024 * | -6M -471M | Net income 2025 * | -5M -392M | EV / Sales 2024 * | 0.6 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.5 x |
P/E ratio 2024 * |
-0.57
x | P/E ratio 2025 * |
-0.71
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.83% |
Latest transcript on ReShape Lifesciences
1 day | +23.84% |
Managers | Title | Age | Since |
---|---|---|---|
Paul Hickey
CEO | Chief Executive Officer | 59 | 31/01/20 |
Director of Finance/CFO | 63 | 14/06/21 | |
Dov Gal
CMP | Compliance Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Gary Blackford
BRD | Director/Board Member | 66 | 31/12/15 |
Dan Gladney
CHM | Chairman | 70 | 31/10/15 |
Director/Board Member | 70 | 14/06/21 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.01% | 217B | |
+11.01% | 190B | |
+19.20% | 143B | |
+30.79% | 111B | |
+1.48% | 64.59B | |
+13.95% | 52.36B | |
-0.16% | 48.45B | |
-6.20% | 38.03B | |
+0.91% | 35.6B |
- Stock Market
- Equities
- RSLS Stock
- RSLS Stock